Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Cohen

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Antiviral Therapy|March 27, 2009
Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alonePhilippe Flandre, Constance Delaugerre, Jade Ghosn, et al.
AIDS (London, England)|January 16, 2008
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsJean-François Delfraissy, Philippe Flandre, Constance Delaugerre, et al.
Cancer Research|January 25, 2003
Bcl-2 and Bax modulate adenine nucleotide translocase activityAnne-Sophie Belzacq, Helena L A Vieira, Florence Verrier, et al.
Current HIV Research|January 5, 2011
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trialSami Kolta, Philippe Flandre, Philippe Ngo Van, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapyConstance Delaugerre, Philippe Flandre, Marie Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2012
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practiceSidonie Lambert-Niclot, Bernard Masquelier, Isabelle Cohen Codar, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Isabelle Cohen-Codar, Martin S King, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Antiviral Therapy|March 27, 2009
Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alonePhilippe Flandre, Constance Delaugerre, Jade Ghosn, et al.
AIDS (London, England)|January 16, 2008
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsJean-François Delfraissy, Philippe Flandre, Constance Delaugerre, et al.
Cancer Research|January 25, 2003
Bcl-2 and Bax modulate adenine nucleotide translocase activityAnne-Sophie Belzacq, Helena L A Vieira, Florence Verrier, et al.
Current HIV Research|January 5, 2011
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trialSami Kolta, Philippe Flandre, Philippe Ngo Van, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapyConstance Delaugerre, Philippe Flandre, Marie Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2012
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practiceSidonie Lambert-Niclot, Bernard Masquelier, Isabelle Cohen Codar, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Isabelle Cohen-Codar, Martin S King, et al.
Pageof 3